VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 107 filers reported holding VAXCYTE INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,598,017 | +2.1% | 325,579 | 0.0% | 0.37% | +26.4% |
| Q2 2023 | $16,259,415 | +5.0% | 325,579 | -21.2% | 0.29% | +23.7% |
| Q1 2023 | $15,490,484 | -41.9% | 413,300 | -25.7% | 0.24% | -27.8% |
| Q4 2022 | $26,655,405 | +212.2% | 555,900 | +56.3% | 0.33% | +220.6% |
| Q3 2022 | $8,537,000 | +10.3% | 355,700 | 0.0% | 0.10% | +13.3% |
| Q2 2022 | $7,740,000 | – | 355,700 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,457,300 | $54,619,604 | 23.40% |
| Pivotal bioVenture Partners Investment Advisor LLC | 693,039 | $25,975,102 | 10.70% |
| RA Capital Management | 7,291,254 | $273,276,200 | 6.19% |
| Kynam Capital Management, LP | 1,216,784 | $45,605,064 | 5.89% |
| GREAT POINT PARTNERS LLC | 659,211 | $24,707,228 | 4.85% |
| Frazier Life Sciences Management, L.P. | 1,397,405 | $52,374,739 | 3.79% |
| ACUTA CAPITAL PARTNERS, LLC | 120,500 | $4,516,340 | 3.33% |
| Ghost Tree Capital, LLC | 225,000 | $8,433,000 | 2.49% |
| Carlyle Group Inc. | 1,923,158 | $72,079,962 | 2.15% |
| Opaleye Management Inc. | 177,000 | $6,633,960 | 1.99% |